Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.

M L Telli, D G Stover, S Loi, S Aparicio, L A Carey, S M Domchek, L Newman, G W Sledge, E P Winer, Breast cancer research and treatment 171, 21-31 (2018)


Triple-negative breast cancer (TNBC) is associated with worse outcomes relative to other breast cancer subtypes. Chemotherapy remains the standard-of-care systemic therapy for patients with localized or metastatic disease, with few biomarkers to guide benefit.